IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Translational Data from OVATION 2 Trial Presented at AACR Special ...

Translational results bolster confidence as Phase III trial for IMNN-001 in advance epithelial ovarian cancer gets underway.

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial ...

People with new-onset type 1 diabetes can achieve similar improvements in C-peptide levels with a 0.5 mg/kg antithymocyte ...

ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine ...

Type 1 diabetes remains a persistent health-care burden despite substantial advances in care. Its preclinical disease course ...

DelveInsight's TL1A Binder Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

The mechanism we delineated … can be targeted at multiple levels with existing drugs, potentially improving disease outcomes in this patient population,” said Lorenzo Galluzzi, PhD.

Scientific Differentiation PLPC-DB™ coordinates innate and adaptive immune responses, enhancing NK and CD8⁺ effector activity and CD4⁺ Th1 polarization. It improves antigen presentation (MHC I/II → ...

Beckman Coulter Life Sciences says its IR820 and IR870 infrared dye antibody conjugates make high-parameter flow cytometry ...

An announcement from Elicio Therapeutics ( ($ELTX) ) is now available. On September 17, 2025, Elicio Therapeutics announced that its ...